HeartSciences Inc. Warrant financials
$0.0437−18.62%
Close Sep 22, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Apr 30 | FY25 Apr 30 | FY24 Apr 30 | FY23 Apr 30 |
|---|---|---|---|---|
| Revenue | $4.3K | $4.3K | $18.6K | $5.2K |
| Gross profit | $2.6K | $2.5K | $12.5K | $2.4K |
| Gross margin | 59.1% | 56.8% | 67.3% | 45.7% |
| Operating income | -$8.4M | -$8.4M | -$6.3M | -$6.1M |
| Net income | -$9.1M | -$8.8M | -$6.6M | -$6.4M |
| Net margin | −211666.5% | −201499.5% | −35511.9% | −123384.3% |
| Diluted EPS | $-3.48 | $-9.34 | $-18.74 | $-79.92 |
| EBITDA | -$8.4M | -$8.3M | -$6.3M | -$6.1M |
| Operating cash flow | -$7.4M | -$7.4M | -$6.1M | -$5.8M |
| Free cash flow | -$7.4M | -$7.4M | -$6.1M | -$5.8M |
| Diluted shares | 2.6M | 0.9M | 0.4M | 0.1M |
Balance sheet
| Period end | Jun 30 | Apr 30 | Apr 30 | Apr 30 | Apr 30 |
|---|---|---|---|---|---|
| Cash & equivalents | $1.7M | $1.7M | $1.1M | $5.8M | $1.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $4.0M | $4.0M | $2.7M | $768.8K | $1.2M |
| Total assets | $5.3M | $5.3M | $4.2M | $9.5M | $3.3M |
| Total liabilities | $5.0M | $5.0M | $4.0M | $2.2M | $3.1M |
| Shareholders' equity | $226.1K | $226.1K | $205.2K | $7.3M | $230.6K |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology